IRVINE, Calif., – Human Options, Orange County's leading organization in ending the cycle of relationship violence, celebrated its tenth annual "Love Shouldn't Hurt" teen dating conference on February ...

Bio-Rad Laboratories Inc (NYSE:BIO). reported its fourth-quarter 2024 earnings, revealing a slight miss on revenue expectations, with net sales of $668 million compared to a forecast of $681.29 ...

Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are interested in meeting ...

Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering portal. For those not attending the conference who are ... s strategy is to develop ...

With our events, we try to create the kind of conference that we would want to attend ourselves, mixing great speakers, insightful content, a forward-thinking outlook and quality networking.

Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor ... or Tosymra are safe and effective in children under ...

Can-Fite will participate in a prominent industry event, the BIO CEO & Investor Conference, which provides a platform for visibility and networking with investors and potential partners.

Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott ...

2025 at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com.

Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 11, 2025 at 10:15 AM EST at the Royale Room and will be available to participate in ...

At this year’s conference, the Speakers, alongside Parliamentary Clerks and constitutional experts, examined different aspects of building strong Legislatures and effective parliamentary democracy.

Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment options. A phase 3 trial with 503 participants ...